Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin to Apply for KRN125 in 2013
January 28, 2013
- Ono, DSP Cancel Development of Limaprost for CTS
January 28, 2013
- Novartis AG: Annual Sales Down, Profits Up, Gilenya Reaches Blockbuster Status
January 28, 2013
- Market for Novel Oral Anticoagulants to Heat Up as More Companies Compete for Low-risk Patients
January 28, 2013
- Otsuka to Hire 55 Grads of 6-Year Pharmaceutical Universities as MRs in FY2013: Jiho Poll
January 25, 2013
- Novartis, Sanofi Dissolve Partnership on Equa Copromotion
January 25, 2013
- AIMIX Ranks No.1, Lotriga Soars in GP Market: Rep Track Survey
January 25, 2013
- JSMI Chief Yoshino Voices Disagreement with JMA on Epadel OTCs
January 25, 2013
- Transparency GL: Drug Makers Might Disclose Individual Payments Only Upon Request
January 24, 2013
- Takeda Establishes Trading Company in China to Serve as Base for Import of Finished Products
January 24, 2013
- Bayer, Santen Aim to Lead Market with Simpler Eylea Administration
January 24, 2013
- Merck Serono Aims for Top 10 Slot in Oncology Field
January 23, 2013
- AZ Initiates First Multinational PI Study under Agreement with NCC
January 23, 2013
- DSP Establishes Subsidiary in Singapore Eyeing Development of Business Operations for Latuda in Asia
January 23, 2013
- Kobayashi Kako, Elmed Eisai Set to Launch Allegra Generics on February 1
January 23, 2013
- Sanofi’s Dellegra Promotion to Home in on Stuffy Nose
January 22, 2013
- Santen Obtains Approval for Preservative-Free Ophthalmic Solution Tapros
January 22, 2013
- Kyorin and Daiichi Sankyo to Cancel Agreement on Uritos in Brazil
January 22, 2013
- Pfizer Detailing Infectious Disease Portfolios across Divisions
January 21, 2013
- Tokyo District Court to Issue Ruling on Actos Patent Suit on Feb. 27 after Takeda Lost Legal Battle in Osaka
January 21, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…